Several reports have suggested that in tumors with low T cell infiltration, the combined blockade of the PD-L1 checkpoint and TGF-β signaling pathway can enhance CD8+ T cell infiltration in TME and stimulate strong anti-tumor immunity (64, 65). This evidence concerns the gene CD8A and neoplasm.